Compare CCS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | NUVB |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2014 | N/A |
| Metric | CCS | NUVB |
|---|---|---|
| Price | $57.79 | $4.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $70.50 | $11.38 |
| AVG Volume (30 Days) | 206.8K | ★ 4.6M |
| Earning Date | 04-22-2026 | 03-02-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.86 | N/A |
| Revenue | ★ $4,117,816,000.00 | N/A |
| Revenue This Year | N/A | $182.76 |
| Revenue Next Year | $10.84 | $91.83 |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.42 | $1.57 |
| 52 Week High | $76.00 | $9.75 |
| Indicator | CCS | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 35.73 |
| Support Level | $56.72 | $4.16 |
| Resistance Level | $66.17 | $5.55 |
| Average True Range (ATR) | 1.77 | 0.22 |
| MACD | -0.26 | 0.01 |
| Stochastic Oscillator | 32.73 | 27.29 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.